A delivery device or patch is disclosed that includes a detachable hybrid microneedle depot (d-HMND) for cell delivery. The system includes, in one embodiment, an array of microneedles formed from an outer PLGA shell and an internal gelatin methacryloyl (GelMA)-mesenchymal stem cells (MSC) mixture (GMM). The array of microneedles project from a base substrate layer that may be flexible. The therapeutic device may be applied to a tissue site of interest and the base substrate layer is removed leaving the hybrid microneedles in the tissue at the site of application to deliver MSCs. Other stem/therapeutic cells may also be delivered with the hybrid microneedles.

A delivery device or patch is disclosed that includes a detachable hybrid microneedle depot (d-HMND) for cell delivery. The system includes, in one embodiment, an array of microneedles formed from an outer PLGA shell and an internal gelatin methacryloyl (GelMA)-mesenchymal stem cells (MSC) mixture (GMM). The array of microneedles project from a base substrate layer that may be flexible. The therapeutic device may be applied to a tissue site of interest and the base substrate layer is removed leaving the hybrid microneedles in the tissue at the site of application to deliver MSCs. Other stem/therapeutic cells may also be delivered with the hybrid microneedles.

This disclosure relates to systems, compounds and methods for stem cell delivery. More specifically, the disclosure relates a system for promoting tissue regeneration, the system comprising a plurality of stem cells coated with at least one or a plurality of dendrimer nanocarriers that specifically bind to an adhesion molecule. Additionally, the disclosure relates to methods for delivering stem cells to damaged or diseased tissue for stem cell regeneration of the tissue.

This disclosure relates to systems, compounds and methods for stem cell delivery. More specifically, the disclosure relates a system for promoting tissue regeneration, the system comprising a plurality of stem cells coated with at least one or a plurality of dendrimer nanocarriers that specifically bind to an adhesion molecule. Additionally, the disclosure relates to methods for delivering stem cells to damaged or diseased tissue for stem cell regeneration of the tissue.

Mesenchymal stem cells (MSCs) or a pharmaceutical composition comprising a therapeutically effective amount of MSCs can be used in the treatment of atopic dermatitis (AD) in canines and felines. In a second aspect, the MSCs or a pharmaceutical composition comprising a therapeutically effective amount of MSCs can be used as an immunomodulating agent during the acute and/or the chronic phase of the AD inflammatory reaction in canines and felines diagnosed with or suffering from atopic dermatitis. In a last aspect, a pharmaceutical composition comprises peripheral blood-derived MSCs.

Mesenchymal stem cells (MSCs) or a pharmaceutical composition comprising a therapeutically effective amount of MSCs can be used in the treatment of atopic dermatitis (AD) in canines and felines. In a second aspect, the MSCs or a pharmaceutical composition comprising a therapeutically effective amount of MSCs can be used as an immunomodulating agent during the acute and/or the chronic phase of the AD inflammatory reaction in canines and felines diagnosed with or suffering from atopic dermatitis. In a last aspect, a pharmaceutical composition comprises peripheral blood-derived MSCs.

Mesenchymal stem cells (MSCs) or a pharmaceutical composition comprising a therapeutically effective amount of MSCs can be used in the treatment of chronic gingivostomatitis (CGS) in subjects, preferably in felines and canines. In a second aspect, MSCs or a pharmaceutical composition comprising a therapeutically effective amount of MSCs can be used as an immunomodulating agent during the acute and/or the chronic phase of the CGS inflammatory reaction in subjects, preferably in felines and canines diagnosed with or suffering from chronic gingivostomatitis. In a last aspect, a pharmaceutical composition can comprise peripheral blood-derived MSCs.

Mesenchymal stem cells (MSCs) or a pharmaceutical composition comprising a therapeutically effective amount of MSCs can be used in the treatment of chronic gingivostomatitis (CGS) in subjects, preferably in felines and canines. In a second aspect, MSCs or a pharmaceutical composition comprising a therapeutically effective amount of MSCs can be used as an immunomodulating agent during the acute and/or the chronic phase of the CGS inflammatory reaction in subjects, preferably in felines and canines diagnosed with or suffering from chronic gingivostomatitis. In a last aspect, a pharmaceutical composition can comprise peripheral blood-derived MSCs.

Mesenchymal stem cells (MSCs) or a pharmaceutical composition comprising a therapeutically effective amount of MSCs can be used in the treatment of chronic kidney disease in felines and canines. Creatinine levels in felines and canines diagnosed with or suffering from chronic kidney disease can be reduced compared to a feline or canine which has not been treated with said MSCs or composition. A pharmaceutical composition comprises MSCs derived from peripheral blood.

Mesenchymal stem cells (MSCs) or a pharmaceutical composition comprising a therapeutically effective amount of MSCs can be used in the treatment of chronic kidney disease in felines and canines. Creatinine levels in felines and canines diagnosed with or suffering from chronic kidney disease can be reduced compared to a feline or canine which has not been treated with said MSCs or composition. A pharmaceutical composition comprises MSCs derived from peripheral blood.